Compounds that selectively eliminate tumor cells with an aberrant genotype may provide a greater therapeutic index and allow for genotype-based patient selection. After screening >1 million compounds for those with oncogenic-RAS-selective-lethality, we have identified four oncogenic-Ras-selective lethal scaffolds (RSL scaffolds) that we named erastin, RSL3, ML162 and SRS7-31. We have elucidated key aspects of their mechanism of action, including: (1) these compounds are more potent in tumor cells with constitutive activation of the RAS-RAF- MEK pathway, (2) they cause a form of iron-dependent oxidative cell death that is morphologically, genetically and biochemically distinct from apoptosis, necrosis, autophagic cell death and necroptosis, which we have termed ferroptosis, and (3) they ultimately cause tumor- selective lipid peroxidation, resulting in membrane damage and non-apoptotic cell death. Here, we seek to test and extend our hypothesis that tumors harboring activated RAS-RAF- MEK signaling are sensitized to ferroptosis. This hypothesis will be evaluated in vitro and in vivo, as these compounds are validated, to move testing of this mechanism and these compounds towards a clinical setting. The significance of the proposed research is that it will result in validation of a set of lead compounds and associated mechanisms that allow for selective targeting of tumor cells harboring oncogenic mutations in Ras pathway genes, especially pancreatic cancers, almost all of which have activating KRAS mutations.
Our goal is to test and extend our hypothesis that tumor cells harboring activating mutations in RAS genes are sensitized to a newly discovered form of non-apoptotic cell death. Furthermore, we aim to create optimized compounds that could eventually serve as therapeutic agents for patients with tumors containing these genetic alterations.
|Skouta, Rachid; Dixon, Scott J; Wang, Jianlin et al. (2014) Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc 136:4551-6|
|Linkermann, Andreas; Stockwell, Brent R; Krautwald, Stefan et al. (2014) Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol 14:759-67|
|Cantley, Alexandra M; Welsch, Matthew; Ambesi-Impiombato, Alberto et al. (2014) Small Molecule that Reverses Dexamethasone Resistance in T-cell Acute Lymphoblastic Leukemia (T-ALL). ACS Med Chem Lett 5:754-9|
|Yang, Wan Seok; SriRamaratnam, Rohitha; Welsch, Matthew E et al. (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317-31|
|Dixon, Scott J; Patel, Darpan N; Welsch, Matthew et al. (2014) Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3:e02523|
|Julien, Olivier; Kampmann, Martin; Bassik, Michael C et al. (2014) Unraveling the mechanism of cell death induced by chemical fibrils. Nat Chem Biol 10:969-76|
|Wolpaw, Adam J; Stockwell, Brent R (2014) Multidimensional profiling in the investigation of small-molecule-induced cell death. Methods Enzymol 545:265-302|
|Dixon, Scott J; Stockwell, Brent R (2014) The role of iron and reactive oxygen species in cell death. Nat Chem Biol 10:9-17|
|Basu, Amrita; Bodycombe, Nicole E; Cheah, Jaime H et al. (2013) An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154:1151-61|
|Varma, Hemant; Gangadhar, Nidhi M; Letso, Reka R et al. (2013) Identification of a small molecule that induces ATG5-and-cathepsin-l-dependent cell death and modulates polyglutamine toxicity. Exp Cell Res 319:1759-73|
Showing the most recent 10 out of 32 publications